Liberation Labs

Liberation Labs, which rebranded to Liberation Bioindustries in June 2025, was established in 2022 to address a critical bottleneck in the biotechnology sector: the lack of large-scale, purpose-built manufacturing capacity for precision fermentation. Founded by CEO Mark Warner and Etan Bendheim, the company acts as a contract manufacturer, providing the necessary infrastructure for companies to commercialize novel bio-based products. Warner, an engineer by trade, has an extensive background in scaling up operations for companies in biofuels, biochemicals, and food, including stints at Solazyme and Impossible Foods. This experience highlighted the challenge for science-driven startups to also master large-scale manufacturing, leading to the formation of Liberation Bioindustries to bridge this gap.

The company's business model centers on designing, building, and operating state-of-the-art precision fermentation facilities. This enables clients—ranging from well-funded startups to established CPG companies—to produce ingredients at a scale and cost structure that allows them to compete with traditional products. By offering contract manufacturing services, Liberation Bioindustries allows innovators to focus on technology development rather than capital-intensive facility construction. Clients can rent capacity to produce a wide array of products, including proteins, specialty chemicals, pharmaceutical ingredients, and other advanced materials.

The company's flagship project is a $115 million facility in Richmond, Indiana, which broke ground in June 2023. This plant, expected to commence commercial production in 2025, will feature an initial fermentation capacity of 600,000 liters. The Indiana location was strategically chosen for its proximity to essential resources like corn dextrose (a key feedstock), power, water, and a skilled manufacturing workforce. The facility is engineered to be flexible, capable of handling various feedstocks and operating scenarios. Upon launch, it's projected to generate significant revenue and has already attracted letters of intent from potential customers that exceed 200% of its available capacity for the initial years. The company has a global expansion plan, with intentions to build facilities in six key geographies, including the Middle East, Australia, and Europe, starting with a launch facility and eventually scaling to a larger four-million-liter plant in each region.

Keywords: precision fermentation, contract manufacturing, biomanufacturing, alternative proteins, cellular agriculture, industrial biotechnology, food tech, sustainable ingredients, bio-based products, CDMO, fermentation capacity, synthetic biology, downstream processing, bio-chemicals, novel foods, food ingredients, biopharmaceuticals, Mark Warner, Liberation Bioindustries, Richmond Indiana